Standard BioTools swaps preferred for common stock
Investing.com | Editor Emilio Ghigini
Published Mar 18, 2024 08:28AM ET
SOUTH SAN FRANCISCO, Calif. - Standard BioTools Inc. (NASDAQ:LAB), a provider of next-generation technologies for biomedical research, announced today that it has completed an exchange of its Series B Convertible Preferred Stock for common stock. The agreement involved stockholders affiliated with Viking Global Investors and Casdin Capital.
Thomas Carey, Chairman of Standard BioTools' Board of Directors, expressed satisfaction with the transaction, emphasizing its potential to attract new investors and M&A partners. Michael Egholm, President and CEO, highlighted the company's strategic focus on operational excellence and disciplined mergers and acquisitions as a means to drive growth and stockholder value.
Under the terms of the agreement, approximately 93 million shares of common stock were issued at $2.75 per share in exchange for all outstanding Series B Preferred Stock. This exchange rate resulted in the issuance of around 17.8 million additional common shares compared to the original conversion price of $3.40 per share, representing less than 5% dilution.
The transaction also eliminated the Series B Preferred's senior rights, including a $250 million liquidation preference and certain governance rights, simplifying the company's capital structure.
The completion of this exchange has increased the total outstanding common stock to approximately 382.5 million shares. TD Cowen and Mintz, Levin, Cohn, Ferris, Glovesky, and Popeo provided financial and legal advisory services, respectively, to the Special Committee of the Board of Directors during the transaction.
This move is part of Standard BioTools' broader strategy to streamline operations and enhance value for stockholders in a competitive market. The company, formerly known as Fluidigm (NASDAQ:LAB) Corporation, is known for its mass cytometry and microfluidics technologies, which are utilized in various research fields including oncology, immunology, and immunotherapy.
The information in this article is based on a press release statement from Standard BioTools Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.